9021 Preliminary results of MAGE-A3 expression and baseline demographic data from MAGRIT, a large phase III trial of MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) in adjuvant NSCLC

M.Zielinski; U.Laskowski; R.Bieselt; M.Reck; J.Strausz; J.Perdeus; K.Park; D.Atanackovic; M.Debois; C.Debruyne

首页> 外文期刊>European Journal of Cancer Supplements >9021 Preliminary results of MAGE-A3 expression and baseline demographic data from MAGRIT, a large phase III trial of MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) in adjuvant NSCLC

【24h】

9021 Preliminary results of MAGE-A3 expression and baseline demographic data from MAGRIT, a large phase III trial of MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) in adjuvant NSCLC

机译：9021来自MAGRIT的MAGE-A3表达和基线人口统计学数据的初步结果，MAGRIT是MAGE-A3 ASCI（抗原特异性癌症免疫治疗剂）在佐剂NSCLC中进行的大型III期试验

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共2页
作者
M.Zielinski; U.Laskowski; R.Bieselt; M.Reck; J.Strausz; J.Perdeus; K.Park; D.Atanackovic; M.Debois; C.Debruyne;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献

1. PP55 A MAGE-A3 specific quantitative RT-PCR assay used for patient accrual in MAGRIT, a Phase III ASCI (Antigen-Specific Cancer Immunotherapeutic) trial in adjuvant NSCLC [J] . T.Coche, J.Louahed, O.Gruselle, European Journal of Cancer Supplements . 2009,第4期

机译：PP55一种用于MAGE-A3特异性定量RT-PCR测定法，用于在MAGRIT中进行患者应计，这是辅助NSCLC的III期ASCI（抗原特异性癌症免疫治疗）试验
2. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial [J] . Vansteenkiste Johan F., Cho Byoung Chul, Vanakesa Tonu, The lancet oncology . 2016,第6期

机译：MAGE-A3癌症免疫治疗作为切除MAGE-A3阳性非小细胞肺癌（MAGRIT）患者的辅助治疗的有效性：一项随机，双盲，安慰剂对照的3期临床试验
3. 6514 ORAL Adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study evaluating the MAGE-A3 cancer immunotherapeutic [J] . J.Vansteenkiste, M.Zielinski, A.Linder, European Journal of Cancer Supplements . 2007,第4期

机译：IB / II期非小细胞肺癌（NSCLC）的6514口服辅助治疗：评估MAGE-A3癌症免疫治疗的多中心，双盲，随机，安慰剂对照II期研究的最终结果
4. Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics [O] . Evelyne Lerut, Hendrik Van Poppel, Steven Joniau, 2015

机译：膀胱癌患者FFPE组织标本中表达MAGE-A3和PRAME的肿瘤发生率：抗原特异性癌症免疫治疗的潜在目标
5. B1-05: Activity of MAGE-A3 cancer immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled phase II study [O] . Vansteenkiste Johan, Zielinksi Marcin, Linder Albert, 2007

机译：B1-05：MAGE-A3癌症作为IB / II期非小细胞肺癌（NSCLC）辅助治疗的免疫治疗活性：一项多中心，双盲，随机，安慰剂对照的II期研究的最终结果

9021 Preliminary results of MAGE-A3 expression and baseline demographic data from MAGRIT, a large phase III trial of MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) in adjuvant NSCLC

著录项

相似文献

相关主题

期刊订阅